Skip to content
10-Q

Quarterly Report

Neurogene Inc. NGNE

0001404644-25-000041

← back to feed
Filed
May 9, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 14.26M sh
Short Term Investments Q1 2025 · Mar 31, 2025 $221.83M
Short Term Investments Q1 2025 · Dec 31, 2024 $175.82M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $70.77M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $136.59M
Current Liabilities Q1 2025 · Mar 31, 2025 $14.09M
Current Liabilities Q1 2025 · Dec 31, 2024 $15.16M
Total Liabilities Q1 2025 · Mar 31, 2025 $23.51M
Total Liabilities Q1 2025 · Dec 31, 2024 $25.36M
Current Assets Q1 2025 · Mar 31, 2025 $296.4M
Current Assets Q1 2025 · Dec 31, 2024 $315.92M
Total Assets Q1 2025 · Mar 31, 2025 $315.3M
Total Assets Q1 2025 · Dec 31, 2024 $335.73M
Shares Diluted Q1 2025 · Mar 31, 2024 16.9M sh
Capex Q1 2025 · Mar 31, 2024 $65K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$21.65M
Stockholders Equity Q1 2025 · Mar 31, 2024 $170.78M
Stockholders Equity Q1 2025 · Dec 31, 2023 $186.02M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.00
Eps Basic Q1 2025 · Mar 31, 2024 −$1.00
Sga Expense Q1 2025 · Mar 31, 2024 $5.24M
Rd Expense Q1 2025 · Mar 31, 2024 $13.54M
Net Income Q1 2025 · Mar 31, 2024 −$16.92M
Operating Income Q1 2025 · Mar 31, 2024 −$18.78M